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Bariatric surgery as a treatment for metabolic 
syndrome
P Cordero1, J Li2, JA Oben3
Obesity is the pandemic of the 21st century. Obesity comorbidities, including 
hypertension, dyslipidaemia and glucose intolerance de ne metabolic 
syndrome, which increases mortality risk and decreases the quality of life. 
Compared with lifestyles (diet and physical activity) and pharmacological 
interventions, bariatric surgery is by far the most effective treatment for 
obesity and its comorbidities. This minimally invasive surgical treatment is 
based on an increase of satiety (by hormonal regulation and decreasing stomach volume) or a 
decrease in nutrient retention (gastric and/or intestinal resection). Bariatric surgery has widely 
demonstrated a bene cial effect on excess body weight loss, cardiovascular risk, dyslipidaemia, 
non-alcoholic fatty liver disease or glucose homeostasis, among other obesity-related metabolic 
diseases. This review describes current efforts for the implementation of bariatric surgery in 
metabolic syndrome, which are mainly focused on the formulation of key de nition criteria for 
targeting the most suitable population for this therapeutic approach. Patients should undergo 
appropriate nutritional and psychological follow up in order to achieve and maintain weight 
loss milestones and a healthy metabolic status.
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Abstract
Introduction
Obesity is a chronic disease characterised by a state 
of inflammation with elevated inflammatory markers. 
Physiologically, obesity is defined as an increase in 
body weight associated with excess adipose tissue 
accumulation.1,2 Obesity has become the main health 
challenge in Western societies with a prevalence of 25% in 
the UK, and, alarmingly, a prevalence of more than 60% of 
overweight adults.2 The main causes of this multifactorial 
disease are lifestyle (diet and physical activity) and genetic 
(and epigenetic) inheritance, promoting the development of 
associated comorbidities and in some cases, malignancies, 
requiring urgent targeted treatments and strict healthcare 
control.3,4,5 As consequences of obesity, the prevalence 
of insulin resistance and type 2 diabetes, cardiovascular 
and cerebrovascular diseases, non-alcoholic fatty liver and 
non-alcoholic fatty pancreas diseases are increasing in 
prevalence and causing a huge economic burden.6
Lifestyle interventions, with or without the combination of 
weight loss drugs, lead to modest weight loss. However, in 
most cases, the results are not maintained in the long-term. 
Bariatrics has been shown to exceed the success of other 
treatment modalities that are available today against obesity 
and its comorbidities.7,8,9 Compared to lifestyle interventions, 
glycaemic control, dyslipidaemia, cardiovascular risk and 
quality of life are more likely to improve after bariatric surgery. 
In addition, bariatric surgery is a long-term cost-effective 
successful intervention. Indeed, this therapeutic approach 
has shown a reduction in the relative risk of death by 89% in 
morbidly obese patients who undergo bariatric surgery, when 
compared with those who do not.10
Metabolic syndrome
Obesity is the main cause of metabolic syndrome. Although 
the deﬁ nition criteria of metabolic syndrome can be adapted 
according to ethnicity or geographic area, the most common 
criteria in Western societies include waist circumference ≥ 
94 cm (male) and ≥ 80 cm (female) plus at least two of the 
following parameters: hypertriglyceridemia (triglyceride levels 
> 1.7 mmol/L or > 150 mg/dL), low HDL cholesterol (HDL 
cholesterol levels < 1.4 mmol/L or < 40 mg/dL [males] and 
< 1.2 mmol/L or < 50 mg/dL [females]), hypertension (≥ 
130 mmHg for systolic blood pressure and ≥ 85 mmHg for 
diastolic blood pressure) or hyperglycaemia/insulin resistance 
(glucose levels ≥ 5.6 mmol/L or ≥ 100 mg/dL).11,12
Therapeutic interventions in metabolic syndrome can be 
speciﬁ ed against each one of the associated diseases using, 
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for example, anti-hypertensives, statins or hypoglycaemic 
drugs.13,14 Obesity remains an elusive therapeutic target. It 
is widely demonstrated that weight reduction is essential for 
patients with metabolic syndrome and other obesity-related 
comorbidities.9,15,16 
Therefore, to target body weight reduction, most of the 
treatments are based on dietary interventions, lifestyle 
modiﬁ cations, anti-obesogenic drugs, bariatric surgery and 
a combination of methods.11,13,14 By far, bariatric surgery is 
the most effective single therapy. For example, in a study 
including obese patients with uncontrolled type 2 diabetes, 
12 months of intensive medical therapy plus bariatric surgery 
achieved glycaemic control in signiﬁ cantly more patients than 
medical therapy alone.17 Furthermore, in a meta-analysis of 
randomised controlled trials comparing bariatric against 
non-bariatric treatment, those patients allocated to bariatric 
surgery had greater improvement in glucose homeostasis, 
body weight loss, plasma triglyceride levels and HDL 
cholesterol.18 Finally, in a meta-analysis including more than 
22,000 patients, type 2 diabetes was improved or resolved 
in 83% of cases, hypercholesterolemia improved in 96%, and 
hypertension resolved or improved in 87% of patients who 
underwent bariatric surgery.19
Bariatric surgery
Bariatric surgery improves metabolic syndrome by body 
weight reduction and, speciﬁ cally, loss of visceral adipose 
tissue excessive depots. This improvement and remission 
of obesity and its comorbidities after bariatric surgery is 
likely to be due to a combination of body weight reduction 
associated with gastric volume restriction and malabsorption 
together with hormonal alterations related to appetite 
and other metabolic and physiological features. Gastric 
restriction results in earlier satiety, which leads to a lower 
food intake thus lowering the glucose load that the body 
has to manage. Additionally, intestinal resection leads to a 
malabsortive process and, therefore, a decrease of nutrient 
(and calorie) availability.8,20
There are different types of bariatric surgery interventions. 
Laparoscopic surgery rather than open surgery is now 
used in the majority of operations, minimising surgery-
associated mortality rates and postoperative complications. 
The availability of different surgical options means that a 
more personalised intervention can be offered to patients. 
The most common procedures carried out in the NHS are 
laparoscopic adjustable gastric banding , laparoscopic Roux-
en-Y gastric bypass and laparoscopic sleeve gastrectomy.8,9 
A study by Angrisani et al. estimated that the total number 
of bariatric procedures performed worldwide in 2013 was 
468,609, of which 95.7% were carried out laparoscopically. 
The most commonly performed procedure was Roux-en-Y 
gastric bypass (45%); followed by sleeve gastrectomy (37%), 
which is the most frequently performed procedure in the 
USA; and adjustable gastric band (10%).21 Depending on the 
speciﬁ c intervention, the digestive physiology of patients is 
altered in a different way, with postoperative healthcare and 
follow up adapted to these speciﬁ c changes. However, the 
main goal after all bariatric surgeries is the loss of body weight. 
Although the main mechanism of weight loss in bariatric 
surgery is clearly the restriction of food intake and/
or absorption, there are other molecular or metabolic 
mechanisms involved. There is hormonal involvement 
implicating gastrointestinal peptides such as glucagon-
like peptide 1, peptide YY, ghrelin, gastrin, glucagon and 
cholecystokinin.22 It has been shown that following Roux-en-Y 
gastric bypass, patients had increased postprandial plasma 
peptide YY and glucagon-like peptide 1 favouring enhanced 
satiety and insulin release. However, these changes were 
not observed after gastric banding intervention, which 
demonstrated that hormonal changes depend on the kind of 
bariatric intervention.23 
Moreover, it has been shown that after bariatric surgery, there 
is a reduction in inﬂ ammatory markers such as alpha1-acid 
glycoprotein, monocyte chemoattractant protein-1, tumour 
necrosis factor- alpha and C-reactive protein, as well as 
in oxidative stress markers such as malondialdehyde, 
superoxide dismutase, catalase, glutathione and 
disulphide.24,25 Interestingly, parallel to these physiological 
adaptations, microbiota proﬁ le alterations after bariatric 
surgery could also affect the physio-metabolic variations of 
the patient.26
Targeting metabolic syndrome by bariatric 
surgery
Not all patients are eligible for bariatric surgery as most 
procedures restructure gastrointestinal physiology therefore it 
may permanently affect normal metabolism. It is necessary to 
establish threshold criteria for bariatric surgical interventions 
when dietary/lifestyle and pharmacological interventions are 
insufﬁ cient in improving patients’ wellbeing and quality of life. 
Currently, bariatric surgery is recommended for patients with 
a BMI of 40 kg/m2 or higher and in those with at least a BMI 
of 35 kg/m2 and other obesity comorbidities.8,9 Besides body 
weight reduction, surgery also results in an improvement of 
insulin resistance or remission of type 2 diabetes.17 Thus, 
bariatric interventions are the most effective treatments 
for patients with obesity complicated type 2 diabetes. 
Comparisons between bariatric surgery interventions with 
intensive medical care point to weight loss as the main 
factor for long-term diabetes improvement.17,27 Weight 
loss associated with bariatric surgery also improves blood 
pressure and plasma lipid proﬁ le as part of cardiovascular 
risk reduction.28,29
Cardiovascular and liver diseases may also beneﬁ t from 
bariatric surgery interventions. There is evidence that 
bariatric surgery improves non-alcoholic fatty liver disease; 
however, the procedure is not considered a treatment option 
for non-alcoholic fatty liver disease.15 A cohort including more 
than 6,000 patients who had undergone bariatric surgery, 
matched with more than 6,000 who had not, presented a 
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49% lower risk of cardiovascular infarction and 59% lower 
cardiovascular-related death in the surgery group that in the 
control group. Furthermore, the risk of death in 5 years was 
approximately 2% for patients after surgery, compared to 6% 
in the control patients.30 Weight loss after bariatric surgery 
also produces substantial decreases in fasting triglyceride 
levels, as well as an elevation of HDL cholesterol levels to 
normality. A cohort of hyperlipidaemic patients after bariatric 
surgery showed that 96% had a reduction in triglyceride levels 
and 83% an increase in HDL cholesterol levels.31
Bariatric surgery in adolescents
It is disturbing that the prevalence of severe obesity is 
about 4–6% in US youths.32 Taking into account the burden 
of obesity comorbidities and the progressive physiological 
damage of this situation, although bariatric surgery incurs in 
a signiﬁ cant initial cost, it could be a cost-effective treatment 
for adolescents with severe obesity.33 
A recent study that included 242 adolescents (mean age 
17 years) with an average pre-operative BMI of 53 kg/m2 
showed, at 3 years after Roux-en-Y gastric bypass or sleeve 
gastrectomy, a decrease of 27% of the initial body weight 
as well as a remission of type 2 diabetes (in 95% of the 
patients with the condition at baseline), prediabetes (76%), 
hypertension (74%) and dyslipidaemia (66%).16 Another long-
term study following up adolescents aged 13–21 years, 8 
years after bariatric surgery, showed a decrease in BMI from 
58.5 to 41.7 kg/m2, prevalence of hypertension from 47% 
to 16%, dyslipidaemia from 86% to 38% and type 2 diabetes 
from 16% to 2%.34 
Follow up after bariatric surgery
Long-term follow-up is strongly advised to avoid postoperative 
surgical, nutritional or psychiatric complications.35,36 In most 
follow ups, maximal weight reduction and obesity comorbidity 
improvements are usually observed during the ﬁ rst two years 
after surgery. However, longer follow up showed that the same 
trends are observed but the magnitude of the differences 
get smaller, with some bodyweight regain. Very few bariatric 
surgery studies report long-term results with sufficient 
patient follow-up to minimise bias. Gastric bypass has better 
outcomes than gastric band procedures for long-term weight 
loss, type 2 diabetes control and remission, hypertension 
and hyperlipidaemia.37
Although bariatric surgery has been the most effective 
treatment for immediate effect, long-term follow up studies 
have shown that the initial remission rate of metabolic 
syndrome associated diseases decreases parallel to time. 
The Swedish Obese Subjects study described a type 2 
diabetes remission rate of 30% at 15 years compared to 
72% at 2 years follow up.38
Most postoperative problems seem to be caused by a lack 
of dietary compliance by the patients. Nutritional education 
and follow up by a professional nutritionist should be 
mandatory in order to achieve long-term improvement in 
patients’ quality of life. Although nutritional deﬁ ciencies 
are commonly analysed during postoperative follow up, 
there is a lack of nutritional diagnosis before intervention. 
Indeed, some of the deﬁ ciencies attributed to the procedure, 
such as iron and vitamin D, could be attributed to a basal 
malnutrition status.35,36,39 Assessment should begin before 
intervention, when a blood proﬁ le nutritional assessment 
should be performed including iron, calcium, phosphorus, 
folic acid, vitamin B12, alkaline phosphatase, 25-hydroxy 
vitamin D, parathyroid hormone, total protein and albumin 
concentrations. With these results, patients should be 
followed up by an expert nutritionist to establish the caloric, 
protein, fat, carbohydrate and micronutrients quality and 
quantity in their diets and the need to reinforce speciﬁ c 
dietary intakes with nutritional supplements (e.g. calcium, 
iron, multivitamin complexes). After surgery, iron deﬁ ciencies 
and anaemia may occur in a higher percentage of patients, 
mainly as a consequence of nutrient deﬁ ciencies.35,36,40
Safety
Bariatric procedures have mortality rates similar to common 
laparoscopic operations. The safest is gastric band, with a 
30-day peri-operative mortality rate of 0.1%; gastric bypass 
is 0.4%. Two years after surgery these rates are 0.0% and 
0.4%, respectively.41,42 As in most surgical interventions, in 
patients aged > 60 years, peri-operative risks and mortality 
rates are higher. Furthermore, patients with morbid obesity 
present a higher risk of suffering thromboembolism. In a 
meta-analysis including more than 160,000 patients with 
bariatric surgery, the mortality rate during the first 30 
postoperative days was 0.08%. It was shown that re-operation 
and other surgical complications were higher in gastric bypass 
interventions compared with adjustable gastric banding and 
sleeve gastrectomy.43 Other studies showed 57% of patients 
presenting with hypoferritinemia and 13% had undergone 
additional intra-abdominal procedures.16 In adolescents, it 
has been shown that 8 years after bariatric surgery, a non-
pathologic below normal cut off point in levels of vitamin B12 
as well as hyperthyroidism in 45% of patients.34
Bariatric endoscopic surgery
A limitation of surgery is the increasing number of patients 
who would beneﬁ t from it.2,44 As such the use of surgery as a 
ﬁ rst line of treatment is not a viable proposition because of 
the of the consequent economic burden. Not all patients want 
surgery or are eligible for this kind of intervention, especially 
given the risk of surgical-related complications and general 
anaesthesia. Endoscopic interventions such as endoscopic 
sleeve gastroplasty, intra-gastric balloon or the EndoBarrier 
may offer less invasive, reversible alternatives s.45–47 
The intra-gastric balloon is a silicone device endoscopically 
inserted into the stomach and-ﬁ lled with saline to a ﬁ xed 
volume. The balloon restricts the volume of the stomach 
without altering its functionality and accelerates satiety.48,49 
The majority of patients undergo uncomplicated insertions 
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and tolerate the therapy with no side effects, which can 
include oesophageal reflux, nausea and vomiting, and 
stomach cramps.50 It is important to highlight that with this 
treatment it is necessary to undergo a nutritional learning 
process in order to change dietary habits and avoid a 
bodyweight rebound after device extraction. The use of intra-
gastric balloon therapy has demonstrated a positive effect 
after 6 months in bodyweight loss parallel to improvements 
in glucose homeostasis, cardiovascular risk and other obesity 
comorbidities.46,51 However, the effect of longer-term use of 
an intra-gastric balloon still requires research. 
Endoscopic sleeve gastroplasty is a novel non-surgical 
procedure whereby the volume of the stomach is limited 
by creating a sleeve with a set of sutures.45,52 In addition 
to sustained total bodyweight loss, endoscopic sleeve 
gastroplasty has been associated with a reduction in 
hypertension, diabetes and hypertriglyceridemia markers.45,52 
The EndoBarrier is a duodenal bypass sleeve anchored to the 
duodenal bulb through a nitinol crown with barbs. The sleeve 
is advanced into the small bowel, allowing undigested food 
to reach the jejunum and creating a physical barrier between 
the food and the intestinal wall.47 Besides a decrease in 
nutrient absorption, EndoBarrier therapy has demonstrated 
a positive effect on glucose metabolism and insulin 
sensitivity in obese and diabetic patients as a coadjutant 
of antihyperglycaemic agents.53
Due to their reversibility, the absence of surgery and general 
anaesthesia, and the demonstrated effectiveness of these 
alternative techniques in treating obesity and its associated 
comorbidities, these bariatric endoscopic procedures 
are gaining much interest among gastroenterologists and 
metabolic physicians. 
Conclusion
Bariatric surgery widely exceeds the success of any 
other treatment modality available today for obesity and 
metabolic syndrome. Although the current usage of bariatric 
surgery is strictly a tool for weight loss and not directly for 
hypertension, dyslipidaemia or glucose homeostasis, these 
conditions are present in the vast majority of metabolic 
syndrome cases with excess bodyweight. Ongoing long-
term studies have highlighted that long-term postoperative 
follow-up is as important as the bariatric intervention and 
strongly advised to avoid postoperative surgical, nutritional 
or psychiatric complications. 
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